Skip to main content
SpringerLink
Log in
Book cover

Melanoma pp 209–229Cite as

Chemotherapy for Melanoma

  • Chapter
  • First Online:

Part of the book series: Cancer Treatment and Research ((CTAR,volume 167))

Abstract

Prior to the recent therapeutic advances, chemotherapy was the mainstay of treatment options for advanced-stage melanoma. A number of studies have investigated various chemotherapy combinations in order to expand on the clinical responses achieved with single-agent dacarbazine, but these have not demonstrated an improvement in overall survival. Similar objective responses were observed with the combination of carboplatin and paclitaxel as were seen with single-agent dacarbazine. The combination of chemotherapy and immunotherapy, known as biochemotherapy, has shown high clinical responses; however, biochemotherapy has not been shown to improve overall survival and resulted in increased toxicities. In contrast, palliation and long-term responses have been observed with localized treatment with isolated limb perfusion or infusion in limb-isolated disease. Although new, improved therapeutic options exist for first-line management of advanced-stage melanoma, chemotherapy may still be important in the palliative treatment of refractory, progressive, and relapsed melanoma. We review the various chemotherapy options available for use in the treatment and palliation of advanced-stage melanoma, discuss the important clinical trials supporting the treatment recommendations, and focus on the clinical circumstances in which treatment with chemotherapy is useful.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Aamdal S, Wolff I et al (1994) Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group. Eur J Cancer 30A(8):1061–1064

    Article  CAS  PubMed  Google Scholar 

  2. Agarwala SS, Kirkwood JM et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22(11):2101–2107

    Article  CAS  PubMed  Google Scholar 

  3. Alexander HR Jr, Fraker DL et al (2010) Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 28(1):114–118

    Article  PubMed Central  PubMed  Google Scholar 

  4. Atkins MB, Hsu J et al (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the eastern cooperative oncology group. J Clin Oncol 26(35):5748–5754

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Bajetta E, Del Vecchio M et al (2002) Metastatic melanoma: chemotherapy. Semin Oncol 29(5):427–445

    Article  CAS  PubMed  Google Scholar 

  6. Bajetta E, Del Vecchio M et al (2006) Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 17(4):571–577

    Article  CAS  PubMed  Google Scholar 

  7. Barbour AP, Thomas J et al (2009) Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol 16(12):3463–3472

    Article  PubMed  Google Scholar 

  8. Beasley GM, Caudle A et al (2009) A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 208(5):706–715, discussion 715–707

    Google Scholar 

  9. Bedikian AY, Weiss GR et al (1995) Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 13(12):2895–2899

    CAS  PubMed  Google Scholar 

  10. Birck A, Kirkin AF et al (1999) Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res 9(4):375–381

    Article  CAS  PubMed  Google Scholar 

  11. Bissery MC, Guenard D et al (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51(18):4845–4852

    CAS  PubMed  Google Scholar 

  12. Bleehen NM, Newlands ES et al (1995) Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13(4):910–913

    CAS  PubMed  Google Scholar 

  13. Bower M, Newlands ES et al (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40(6):484–488

    Article  CAS  PubMed  Google Scholar 

  14. Buzaid AC, Colome M et al (1998) Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 8(6):549–556

    Article  CAS  PubMed  Google Scholar 

  15. Chapman PB, Einhorn LH et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9):2745–2751

    CAS  PubMed  Google Scholar 

  16. Chapman PB, Hauschild A et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Coventry BJ, Kroon HM et al (2014) Australian multi-center experience outside of the Sydney melanoma unit of isolated limb infusion chemotherapy for melanoma. J Surg Oncol

    Google Scholar 

  18. Creagan ET, Suman VJ et al (1999) Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 17(6):1884–1890

    CAS  PubMed  Google Scholar 

  19. Creech O Jr, Krementz ET et al (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148(4):616–632

    Article  PubMed Central  PubMed  Google Scholar 

  20. Crosby T, Fish R et al (2000) Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2:CD001215

    Google Scholar 

  21. Dhomen N, Marais R (2009) BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23(3):529–545, ix

    Google Scholar 

  22. Dillman RO, Church C et al (1993) Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The national biotherapy study group experience. Cancer 71(7):2358–2370

    Article  CAS  PubMed  Google Scholar 

  23. Duprat Neto JP, Mauro AC et al (2012) Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity. ANZ J Surg

    Google Scholar 

  24. Eggermont AM, Kirkwood JM (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40(12):1825–1836

    Article  CAS  PubMed  Google Scholar 

  25. Einzig AI, Hochster H et al (1991) A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 9(1):59–64

    Article  CAS  PubMed  Google Scholar 

  26. Eton O, Legha SS et al (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20(8):2045–2052

    Article  CAS  PubMed  Google Scholar 

  27. Evans LM, Casper ES et al (1987) Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 71(2):171–172

    CAS  PubMed  Google Scholar 

  28. Falchook GS, Lewis KD et al (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13(8):782–789

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Fecher LA, Amaravadi R et al (2008) Effectively targeting BRAF in melanoma: a formidable challenge. Pigm Cell Melanoma Res 21(4):410–411

    Article  Google Scholar 

  30. Fecher LA, Amaravadi RK et al (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20(2):183–189

    Article  CAS  PubMed  Google Scholar 

  31. Flaherty KT, Infante JR et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Flaherty KT, Lee SJ et al (2013) Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 31(3):373–379

    Article  CAS  PubMed  Google Scholar 

  33. Flaherty KT, Robert C et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114

    Article  CAS  PubMed  Google Scholar 

  34. Flaherty LE, Moon J et al (2012) Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG. J Clin Oncol (suppl)

    Google Scholar 

  35. Giles MH, Coventry BJ (2013) Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide melanoma unit. Cancer Manag Res 5:243–249

    PubMed Central  PubMed  Google Scholar 

  36. Gonzalez Cao M, Malvehy J et al (2006) Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. Melanoma Res 16(1):59–64

    Article  PubMed  Google Scholar 

  37. Gorski DH, Leal AD et al (2003) Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg 197(3):408–418

    Article  PubMed  Google Scholar 

  38. Hauschild A, Agarwala SS et al (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27(17):2823–2830

    Article  CAS  PubMed  Google Scholar 

  39. Hauschild A, Grob JJ et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365

    Article  CAS  PubMed  Google Scholar 

  40. Hersh EM, O’Day SJ et al (2011) A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 29(3):489–498

    Article  CAS  PubMed  Google Scholar 

  41. Hersh EM, O’Day SJ et al (2010) A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 116(1):155–163

    CAS  PubMed  Google Scholar 

  42. Hill GJ 2nd, Ruess R et al (1974) Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). Ann Surg 180(2):167–174

    Article  PubMed Central  PubMed  Google Scholar 

  43. Hodi FS, O’Day SJ et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Hodi FS, Soiffer RJ et al (2002) Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25(3):283–286

    Article  PubMed  Google Scholar 

  45. Hoekstra HJ, Veerman K et al (2014) Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion? J Surg Oncol 109(4):338–347

    Article  CAS  PubMed  Google Scholar 

  46. Hofmann MA, Hauschild A et al (2011) Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre dermatologic cooperative oncology group trial. Melanoma Res 21(6):516–523

    Article  PubMed  Google Scholar 

  47. Howlader NNA, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2013

  48. Ives NJ, Stowe RL et al (2007) Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol 25(34):5426–5434

    Article  CAS  PubMed  Google Scholar 

  49. Ji Z, Flaherty KT et al (2010) Molecular therapeutic approaches to melanoma. Mol Aspects Med 31(2):194–204

    Article  CAS  PubMed  Google Scholar 

  50. Jiang G, Li RH et al (2014) Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis. Tumour Biol 35(1):315–322

    Article  CAS  PubMed  Google Scholar 

  51. Kim KB, Kefford R et al (2013) Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31(4):482–489

    Article  CAS  PubMed  Google Scholar 

  52. Kim KB, Legha SS et al (2009) A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 19(1):42–49

    Article  CAS  PubMed  Google Scholar 

  53. Kim KB, Sosman JA et al (2012) BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30(1):34–41

    Article  CAS  PubMed  Google Scholar 

  54. Kirkwood JM, Strawderman MH et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol 14(1):7–17

    CAS  PubMed  Google Scholar 

  55. Klop WM, Vrouenraets BC et al (1996) Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 182(6):467–472

    CAS  PubMed  Google Scholar 

  56. Kroon HM, Huismans AM et al (2014) Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. J Surg Oncol 109(4):348–351

    Article  CAS  PubMed  Google Scholar 

  57. Kroon HM, Moncrieff M et al (2008) Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 15(11):3003–3013

    Article  PubMed  Google Scholar 

  58. Lacal PM, Failla CM et al (2000) Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115(6):1000–1007

    Article  CAS  PubMed  Google Scholar 

  59. Legha SS, Papadopoulos NE et al (1987) Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5(8):1240–1246

    CAS  PubMed  Google Scholar 

  60. Legha SS, Ring S et al (1996) Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7(8):827–835

    Article  CAS  PubMed  Google Scholar 

  61. Legha SS, Ring S et al (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16(5):1752–1759

    CAS  PubMed  Google Scholar 

  62. Legha SS, Ring S et al (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64(10):2024–2029

    Article  CAS  PubMed  Google Scholar 

  63. Legha SS, Ring S et al (1990) A phase II trial of taxol in metastatic melanoma. Cancer 65(11):2478–2481

    Article  CAS  PubMed  Google Scholar 

  64. Lewis KD, Robinson WA et al (2006) Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 24(19):3157–3163

    Article  CAS  PubMed  Google Scholar 

  65. Li Y, McClay EF (2002) Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29(5):413–426

    Article  CAS  PubMed  Google Scholar 

  66. Lienard D, Ewalenko P et al (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10(1):52–60

    CAS  PubMed  Google Scholar 

  67. Marcoval J, Moreno A et al (1997) Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 24(4):212–218

    Article  CAS  PubMed  Google Scholar 

  68. Margolin K, Atkins B et al (2002) Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the cytokine working group. J Cancer Res Clin Oncol 128(4):214–218

    Article  CAS  PubMed  Google Scholar 

  69. Margolin KA, Liu PY et al (1998) Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 16(2):664–669

    CAS  PubMed  Google Scholar 

  70. McClay EF, Mastrangelo MJ et al (1992) Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50(4):553–556

    Article  CAS  PubMed  Google Scholar 

  71. McDermott DF, Mier JW et al (2000) A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 6(6):2201–2208

    CAS  PubMed  Google Scholar 

  72. Mian R, Henderson MA et al (2001) Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 44(3):189–192

    CAS  PubMed Central  PubMed  Google Scholar 

  73. Middleton MR, Grob JJ et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1):158–166

    CAS  PubMed  Google Scholar 

  74. Newlands ES, Stevens MF et al (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23(1):35–61

    Article  CAS  PubMed  Google Scholar 

  75. Nieweg OE, Kroon BB (2014) Isolated limb perfusion with melphalan for melanoma. J Surg Oncol 109(4):332–337

    Article  PubMed  Google Scholar 

  76. Parkinson DR, Abrams JS et al (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 8(10):1650–1656

    CAS  PubMed  Google Scholar 

  77. Patel PM, Suciu S et al (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47(10):1476–1483

    Article  CAS  PubMed  Google Scholar 

  78. Paul MJ, Summers Y et al (2002) Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12(2):175–178

    Article  CAS  PubMed  Google Scholar 

  79. Punt CJ, van Herpen CM et al (1997) Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. Br J Cancer 76(2):266–269

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Pyrhonen S, Hahka-Kemppinen M et al (1992) A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10(12):1919–1926

    CAS  PubMed  Google Scholar 

  81. Qi RQ, He L et al (2011) BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. J Invest Dermatol 131(5):1129–1138

    Article  CAS  PubMed  Google Scholar 

  82. Rao GG, Rogers P et al (2005) Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol 96(1):168–172

    Article  CAS  PubMed  Google Scholar 

  83. Robert C, Thomas L et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526

    Article  CAS  PubMed  Google Scholar 

  84. Rosenberg SA, Yang JC et al (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12):907–913

    Article  CAS  PubMed  Google Scholar 

  85. Rossi CR, Russano F et al (2008) TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial. Ann Surg Oncol 15(4):1218–1223

    Article  PubMed  Google Scholar 

  86. Rusthoven JJ, Quirt IC et al (1996) Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14(7):2083–2090

    CAS  PubMed  Google Scholar 

  87. Sanki A, Kam PC et al (2007) Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 245(4):591–596

    Article  PubMed Central  PubMed  Google Scholar 

  88. Shetty G, Beasley GM et al (2013) Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. Ann Surg Oncol 20(4):1128–1135

    Article  PubMed Central  PubMed  Google Scholar 

  89. Sosman JA, Kim KB et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707–714

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  90. Squires MH 3rd, Delman KA (2013) Current treatment of locoregional recurrence of melanoma. Curr Oncol Rep 15(5):465–472

    Article  CAS  PubMed  Google Scholar 

  91. Steinman J, Ariyan C et al (2014) Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. J Surg Oncol 109(5):405–409

    Article  PubMed  Google Scholar 

  92. Thompson JF, Kam PC et al (1998) Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14(3):238–247

    Article  CAS  PubMed  Google Scholar 

  93. Ugurel S, Rappl G et al (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19(2):577–583

    CAS  PubMed  Google Scholar 

  94. Vuoristo MS, Hahka-Kemppinen M et al (2005) Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res 15(4):291–296

    Article  CAS  PubMed  Google Scholar 

  95. Wilhelm SM, Adnane L et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129–3140

    Article  CAS  PubMed  Google Scholar 

  96. Wolchok JD, Neyns B et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164

    Article  CAS  PubMed  Google Scholar 

  97. Wong J, Chen YA et al (2013) Isolated limb infusion in a series of over 100 infusions: a single-center experience. Ann Surg Oncol 20(4):1121–1127

    Article  PubMed Central  PubMed  Google Scholar 

  98. Yung WK (2000) Temozolomide in malignant gliomas. Semin Oncol 27(3 Suppl 6):27–34

    CAS  PubMed  Google Scholar 

  99. Yung WK, Albright RE et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588–593

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  100. Zimpfer-Rechner C, Hofmann U et al (2003) Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the dermatologic co-operative oncology group (DeCOG). Melanoma Res 13(5):531–536

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, 16 Penn Tower, Philadelphia, PA, 19104, USA

    Melissa A. Wilson

  2. Division of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU School of Medicine, 160 E. 34th Street, Rm 915, New York, NY, 10016, USA

    Melissa A. Wilson

  3. Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center of the University of Pennsylvania, 3400 Civic Center Blvd, 1218 Penn Tower, Philadelphia, PA, 19104, USA

    Lynn M. Schuchter

Authors
  1. Melissa A. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynn M. Schuchter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lynn M. Schuchter .

Editor information

Editors and Affiliations

  1. Rutgers Cancer Institute of New Jersey, New Brunswick, New York, USA

    Howard L. Kaufman

  2. Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA

    Janice M. Mehnert

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Wilson, M.A., Schuchter, L.M. (2016). Chemotherapy for Melanoma. In: Kaufman, H., Mehnert, J. (eds) Melanoma. Cancer Treatment and Research, vol 167. Springer, Cham. https://doi.org/10.1007/978-3-319-22539-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22539-5_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22538-8

  • Online ISBN: 978-3-319-22539-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation